EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer

Xiaoyu Sun, Haiyang Jiang, Yufei Huang, Jing Xia, Jie Gu, Xinbing Sui, Xueni Sun, Yucheng Zhou

PeerJ · 2025

DOI: 10.7717/peerj.19517 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Xiaoyu Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Deoxycytidine, Drug Resistance, Neoplasm, Antimetabolites, Antineoplastic. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation Funded Project, Postdoctoral Research Startup Foundation of Zhejiang Provincial People’s Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic cancer is highly aggressive with limited treatment options. PLA2G16 has been implicated in cancer progression, but its role in prognosis and gemcitabine sensitivity in pancreatic cancer remains poorly understood.

Methods

Using TCGA data, the study assessed the correlation between PLA2G16 expression and patient survival. The expression of PLA2G16 in gemcitabine-resistant versus sensitive pancreatic cancer cells was also compared. siRNA-mediated knockdown of PLA2G16 was performed in drug-resistant PANC-1 cells to evaluate its impact on gemcitabine sensitivity. The relationship between PLA2G16 expression, immune infiltration, and molecular pathways in pancreatic cancer was explored using CIBERSORT and DAVID tools.

Results

PLA2G16 was significantly overexpressed in pancreatic cancer tissues and associated with poorer patient survival. In PANC-1 cells, increased PLA2G16 expression correlated with gemcitabine resistance, and its knockdown improved drug sensitivity. PLA2G16 expression was linked to specific immune infiltration patterns and cancer-related molecular pathways.

Conclusions

Elevated PLA2G16 expression is associated with poor survival and gemcitabine resistance in pancreatic cancer, making it a potential prognostic marker and therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsDeoxycytidineDrug Resistance, NeoplasmAntimetabolites, AntineoplasticHumansGemcitabinePrognosisCell Line, TumorBiomarkers, TumorGene Expression Regulation, NeoplasticFemaleMale

Stichwörter der Autor:innen

Gemcitabine sensitivityImmune infiltrationPLA2G16Pancreatic cancerPrognosis prediction

Substanzen

GemcitabineDeoxycytidineAntimetabolites, AntineoplasticBiomarkers, Tumor

Autor:innen und Institutionen

  • School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.
  • Department of Gastrointestinal & Pancreatic Surgery, Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.

Förderung

  • China Postdoctoral Science Foundation Funded Project
  • Postdoctoral Research Startup Foundation of Zhejiang Provincial People’s Hospital

Zitieren

APA

Sun, X., Jiang, H., Huang, Y., Xia, J., Gu, J., Sui, X., Sun, X., & Zhou, Y. (2025). PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer. PeerJ. https://doi.org/10.7717/peerj.19517

Vancouver

Sun X, Jiang H, Huang Y, Xia J, Gu J, Sui X, et al. PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer. PeerJ. 2025. doi:10.7717/peerj.19517

BibTeX
@article{Sun2025,
  author = {Sun, Xiaoyu and Jiang, Haiyang and Huang, Yufei and Xia, Jing and Gu, Jie and Sui, Xinbing and Sun, Xueni and Zhou, Yucheng},
  title = {PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer},
  journal = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.19517}
}
Kostenlos starten →